5-Amino-1MQ vs MOTS-c

Side-by-side comparison

How they differ in mechanism

5-Amino-1MQ inhibits nicotinamide N-methyltransferase, an enzyme that methylates nicotinamide to produce 1-methylnicotinamide while consuming S-adenosylmethionine. The preclinical literature reports that NNMT inhibition increases intracellular NAD+ availability and shifts the SAM/SAH methylation ratio in adipocytes, promoting a metabolic shift toward increased energy expenditure. The Neelakantan and Dimet-Wiley studies have characterised these effects in cell-culture systems and diet-induced-obesity rodent models.

MOTS-c has a 16-residue sequence encoded by the mitochondrial genome (specifically the 12S rRNA gene) and was first characterised by Lee and colleagues in 2015. The published mechanistic work describes AMPK-pathway activation, nuclear translocation under metabolic stress conditions, and regulation of the nuclear transcriptome. Functional endpoints in rodent models include metabolic homeostasis, improved insulin sensitivity, and exercise-capacity enhancement. The Kim et al. 2018 study characterised the nuclear-translocation mechanism in detail.

Both compounds converge on the broad theme of cellular energy metabolism but through entirely different molecular targets. 5-Amino-1MQ acts on an enzyme in the NAD+ and methyl-donor network. MOTS-c acts through a mitochondrial-signalling and AMPK-activation pathway. They do not share a common receptor, enzyme target, or signalling cascade in the published literature.

How research has examined each

The 5-Amino-1MQ literature is concentrated in NNMT biochemistry and in rodent models of diet-induced obesity. The Neelakantan fluorescent assay for NNMT activity and the Dimet-Wiley diet-restriction combination study are the primary compound-specific references. The broader NNMT biology literature provides context on the enzyme’s role in adipose-tissue metabolism, cancer-cell proliferation, and NAD+ homeostasis.

The MOTS-c literature has expanded rapidly since the 2015 characterisation study. Published work covers metabolic homeostasis in diet-induced-obesity and insulin-resistance models, exercise physiology (AMPK-PGC-1α axis), neuropathic pain (AMPK-mediated microglia modulation), cardiovascular endpoints, and age-related metabolic decline. The peptide’s mitochondrial origin places it within the broader mitochondrial-derived-peptide (MDP) research field alongside humanin and SHLP peptides.

The two compounds sit at different stages of literature maturity within the metabolic-research space. MOTS-c has a broader and more rapidly expanding published literature across multiple organ systems and endpoint categories. 5-Amino-1MQ has a more focused literature concentrated on adipose-tissue NNMT biology. Both remain at the preclinical stage without large-scale clinical trials.

Stacking considerations in research contexts

Combined administration of 5-Amino-1MQ and MOTS-c is not described in the published literature. The molecular targets are unrelated (NNMT enzyme inhibition versus AMPK pathway activation), so no direct pharmacological collision is anticipated, but no published protocol describes the combination. Both compounds are sold as separate vials in the Ronin catalog (5-Amino-1MQ at 50 mg, MOTS-c at 10 mg) for independent sourcing by researchers.

Sourcing both at Ronin

Both compounds in the Ronin catalog ship as lyophilised material in glass vials, capped and crimped, with certificate-of-analysis documentation (mass spec + HPLC purity) on the lab-results page. The 5-Amino-1MQ vial page ships at 50 mg per vial. The MOTS-c vial page ships at 10 mg per vial. Both carry per-compound spec sheets and storage guidance. Both are sold strictly as research-grade reagents for laboratory and bench-research applications.

Frequently asked research questions

References

1. Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 2015. [PMID 25738459]
2. Neelakantan H et al. Noncoupled Fluorescent Assay for Direct Real-Time Monitoring of Nicotinamide N-Methyltransferase Activity. Biochemistry, 2017. [PMID 28121423]
3. Kim KH et al. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metabolism, 2018. [PMID 29983246]
4. Dimet-Wiley A et al. Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. Scientific Reports, 2022. [PMID 35013352]
5. Wan W et al. Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. Journal of Translational Medicine, 2023. [PMID 36670507]